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XBP1 mitigates aminoglycoside-induced endoplasmic
reticulum stress and neuronal cell death
N Oishi1,4,5, S Duscha2,5, H Boukari2,5, M Meyer2, J Xie1,6, G Wei1, T Schrepfer1,2, B Roschitzki3, EC Boettger*,2 and J Schacht*,1
Here we study links between aminoglycoside-induced mistranslation, protein misfolding and neuropathy. We demonstrate that
aminoglycosides induce misreading in mammalian cells and assess endoplasmic reticulum (ER) stress and unfolded protein
response (UPR) pathways. Genome-wide transcriptome and proteome analyses revealed upregulation of genes related to protein
folding and degradation. Quantitative PCR confirmed induction of UPR markers including C/EBP homologous protein, glucose-
regulated protein 94, binding immunoglobulin protein and X-box binding protein-1 (XBP1) mRNA splicing, which is crucial for UPR
activation. We studied the effect of a compromised UPR on aminoglycoside ototoxicity in haploinsufficient XBP1 (XBP1+/− ) mice.
Intra-tympanic aminoglycoside treatment caused high-frequency hearing loss in XBP1+/− mice but not in wild-type littermates.
Densities of spiral ganglion cells and synaptic ribbons were decreased in gentamicin-treated XBP1+/− mice, while sensory cells
were preserved. Co-injection of the chemical chaperone tauroursodeoxycholic acid attenuated hearing loss. These results suggest
that aminoglycoside-induced ER stress and cell death in spiral ganglion neurons is mitigated by XBP1, masking aminoglycoside
neurotoxicity at the organismal level.
Cell Death and Disease (2015) 6, e1763; doi:10.1038/cddis.2015.108; published online 14 May 2015
Translational fidelity is maintained throughout all three
domains of life (archea, bacteria and eukaryota), suggesting
a high selective pressure during evolution to minimize errors in
protein synthesis.1 In bacteria, erroneous protein synthesis
induces protein misfolding.2 In higher eukaryotes, protein
misfolding results in endoplasmatic reticulum (ER) stress and
initiates the unfolded protein response (UPR), a cascade of
integrated pathways regulating gene expression. The UPRER
is mediated by three ubiquitously expressed transmembrane
proteins in the ER: inositol-requiring enzyme 1 (IRE1), PKR-
like ER kinase (PERK) and activating transcription factor 6
(ATF6).3–7 Under normal conditions, the luminal domains of
IRE1, PERK and ATF6 are bound by the ER chaperone-
binding immunoglobulin protein (BiP), which inhibits self-
dimerization and activation of the cytosolic domain.8,9 Under
ER stress, BiP is released resulting in dimerization of IRE1
and ATF6 and oligomerization of PERK, initiating the UPR
signaling cascades.8,9 The initial UPR response is protective,
increasing the expression of chaperone proteins promoting
refolding and, if unsuccessful, the degradation of misfolded
proteins.10–13 Prolonged or severe stress triggers additional
pathways that eventually lead to cellular apoptosis.14–16
Aminoglycoside antibiotics are well known to affect transla-
tional fidelity in bacteria and lower eukaryotes17–20 but
only few reports suggest that aminoglycoside antibiotics
may also induce misreading in higher eukaryotes.21–23
Aminoglycoside-mediated readthrough activity has been
exploited for therapy of human genetic diseases associated
with premature stop codons.24–27 In addition, aminoglycosides
have been shown to induce apoptosis in human cell cultures,
accompanied by ER stress and mitochondrial cytochrome c
release.28,29 It was suggested that the observed ER
stress could be the result of protein misfolding, reflecting
aminoglycoside-induced mistranslation.28 Despite this poten-
tial for misreading induced by aminoglycosides in eukaryotes,
aminoglycoside treatment in experimental animals and in
patients iswell tolerated. Side effects are highly organ specific,
limited to the kidney and the inner ear,30 while toxicity to the
nervous system is not evident even in long-term aminoglyco-
side administration.31 In the case of ototoxicity, the primary
drug target are the sensory hair cells, as convincingly
demonstrated in various animal models, regardless of whether
the drug is given systemically32 or directly introduced into
the cochlea.33 Degeneration of spiral ganglion cells (SGCs)
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observed after ototoxic dosages of aminoglycosides are
thought to occur only as a sequel to the loss of sensory hair
cells in the vast majority of cases. Surprisingly, however, a few
analyses of human temporal bones have suggested that spiral
ganglia can be affected by aminoglycosides without overt
insult to the hair cells.34,35 This rare pathology, unexplained by
the treatment modus, suggests individual variability possibly
based on genetic factors.
Prompted by the anecdotal reports of aminoglycoside-
induced selective spiral ganglion damage and the potential of
aminoglycosides to induce mistranslation, the objective of this
study was to assess the contribution of ER stress to ototoxicity.
We first investigated aminoglycoside-induced misreading and
UPR responses in HEK293 cells in vitro. Next, we examined
the role of ER stress in ototoxicity in cochlear organ cultures of
CBA/J mice. Finally, we used an in vivomouse model36 with a
compromised ER stress response because of X-box binding
protein-1 (XBP1) haploinsufficiency37 in order to probe
potential links between aminoglycoside neurotoxicity, transla-
tion fidelity and protein misfolding.
Results
Aminoglycosides alter translation fidelity. Drug-induced
inhibition of translation was used to assess aminoglycoside
activity on the eukaryotic ribosome. IC50 values were 0.3 μM
for geneticin and 9.8 μM for gentamicin in the cell-free
translation assays with rabbit reticulocyte lysate (RRL), and
4.4 μM for geneticin and 812 μM for gentamicin in assays with
intact HEK293 cells (Supplementary Figures S1a and b). The
ability of the drugs to induce mistranslation was analyzed
using sensitive gain-of-function dual-luciferase assays to
assess near-cognate misreading and stop codon read-
through. Near-cognate misreading was studied using con-
structs with substitution of amino-acid 245 in the active site of
mutated firefly luciferase (wild-type His CAC→ near-cognate
Arg CGC), which results in loss of enzymatic activity with
enzymatic function restored by misreading; stop codon
readthrough was determined using constructs with in-frame
stop codons abolishing firefly luciferase activity. Both
geneticin and gentamicin decreased ribosomal accuracy in
cell-free translation assays (RRL) and in HEK cells in a dose-
dependent manner (Figure 1). Misreading was induced up to
25-fold in RRL and up to 8.5-fold in HEK cells compared with
untreated controls; readthrough was induced up to 20-fold in
RRL and up to 70-fold in HEK cells compared with untreated
controls (Figure 1). In HEK cells transfected with the
aminoglycoside phosphotransferase APH(3′), the geneticin-
induced but not the gentamicin-induced translation inhibition
and mistranslation were abrogated (Supplementary Figures
S1c and d), consistent with the selectivity of the enzyme to
inactivate geneticin but not gentamicin.38,39 Aminoglycoside-
treated and -untreated HEK wild-type cells showed similar
metabolic activities and viability at both the 24-h and 48-h
time points (Supplementary Figures S1e and f).
Aminoglycosides induce genome-wide upregulation of
cellular folding capacity. In order to study the cellular
Figure 1 Aminoglycoside-induced mistranslation. (a–b) Misreading and (c–d) readthrough was measured in RRL (a and c) and HEK wild-type cells (b and d). Results are
derived from the ratio hFluc/hRluc, given in fold induction. Untreated samples are set as 1 (n= 3; ± S.E.M.)
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response to aminoglycoside-induced mistranslation, we used
whole-genome transcriptomic and proteomic analyses.
A microarray analysis of geneticin-treated versus -untreated
cells revealed a broad transcriptional response totaling 705
genes (selected for a fold change 41.2, Benjamini–Hoch-
berg corrected P-value o0.05; Supplementary Figure S2a).
Protein folding and transcription were among the most
enriched functional ontologies (Supplementary Figure S2b),
including the induction of the ER-specific chaperones BiP
(HSPA5), glucose-regulated protein 94 (GRP94; HSP90B1),
calreticulin (CALR), GRP110 (HYOU1), ERdj3 (DNAJB11)
and ERdj6 (DNAJC3), the ER foldases PDIA3 (ERp57),
PDIA4 (ERp70), ERp44 and FKBP7, and the N-linked
glycosylation factor SDF2L1. Similarly, ER-associated degra-
dation (ERAD) components such as VCP (p97), Derlin2
(DERL2) and Herp (HERPUD1) were significantly upregu-
lated (Supplementary Figure S2c). This transcriptional
response indicates a broad increased folding and degrada-
tion capacity in the ER. In addition, a large number of
cytosolic chaperones40 were upregulated, such as members
of the Hsp40, Hsp70, Hsp90 and Hsp110 families and to a
lesser extent foldases (peptidyl-prolyl cis/trans isomerases
and protein disulfide isomerases; Supplementary Figures
S2d and e), indicating an increased folding capacity in the
cytosol. Supplementary Table S1 lists the genes included in
the analysis. The microarray data have been deposited in
NCBI's Gene Expression Omnibus and are accessible
through GEO Series accession number GSE57198 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57198).
Proteome analysis found 77 proteins to be regulated by
geneticin (Bonferroni-corrected P-valueo0.05). When apply-
ing a minimum fold induction of 0.3 (log2 scale) we identified
35 proteins that were upregulated. Grouping according to
function revealed a predominance of proteins involved in
protein folding (Figure 2a). Proteins associated with the ER
and cytoplasmic UPR, such as BiP, GRP94, calreticulin,
foldases, and members of the Hsp70, Hsp90, Hsp110 and
Hsp40 families, were also upregulated (Figure 2b). Compar-
ison with corresponding mRNA levels showed an upregulation
of the folding machinery both at the transcriptomic and the
proteomic level (Figure 2c). The mass spectrometry proteo-
mics data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository with the data set
identifier PXD000933 and DOI 10.6019/PXD000933.
Aminoglycosides induce the UPR. To corroborate the
results of the microarray analysis, mRNA levels of selected
UPR genes were further analyzed by quantitative PCR and
corresponding protein levels assessed by western blotting.
Geneticin and gentamicin-induced mRNA expression of
Figure 2 Proteomic analysis of geneticin-treated HEK wild-type cells. (a) Thirty-five upregulated proteins (Bonferroni-corrected P-valueo0.05, log2 FC40.3) were grouped
according to their biological function. (b) Upregulation of the geneticin-induced heat shock proteins, chaperones and foldases (Bonferroni-corrected P-value o0.05,
log2 FC40.3). (c) Comparison of the significantly regulated proteins (Bonferroni-corrected P-value o0.05) and their corresponding mRNA fold induction. The upregulated
proteins of the folding machinery are shown in red
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C/EBP homologous protein (CHOP), GRP94 and BiP in a
time-dependent manner (Figures 3a–c). Increased protein
levels of the two ER chaperones BiP and GRP94, as well as
the transcription factor ATF4, which is regulated at the
translational level,41 were observed in geneticin- and
gentamicin-treated cells by western blotting (Figure 3e).
Figure 3 Aminoglycosides induce the UPR. (a–c) qPCR analysis. HEK wild-type cells were treated with geneticin (16 μM) or gentamicin (400 μM) and incubated for the
indicated times. Expression of mRNA for CHOP (a), BiP (b) and GRP94 (c) is shown. Means+S.D. of fold induction are presented relative to 0 h (untreated) sample (n= 3);
*Po0.05; **Po0.01; ***Po0.005; ****Po0.001. (d) XBP1-splicing assay. HEK wild-type or HEK aph(3′) cells were treated with geneticin (16 μM), gentamicin (1250 μM),
hygromycin (2 μM), cycloheximide (2 μM), tunicamycin (5 μg/ml) for 24 h or left untreated. NTC, no template control. PCR products of XBP1 were analyzed by gel
electrophoresis; unspliced and spliced versions of XBP1 are indicated. Tunicamycin was a positive control to induce ER stress; GAPDH was a loading control. The asterisk
indicates the position of a hybrid amplicon.15 (e) Western blot analysis. HEK wild-type cells were treated with geneticin (16 μM) or gentamicin (400 μM) and incubated for 24 h. Ten
micrograms of total protein were loaded and BiP, GRP94 and ATF4 were detected by immunoblotting using specific antibodies. β-Actin was used as a loading control and
tunicamycin (2.5 μg/ml) as a positive control. (f and g) Reporter assays. HEK cells were transfected with luciferase reporter plasmids (f) UPRE (reporter for ATF6 activity) or (g)
ERSE (reporter for ATF6 and XBP1 activity). Cells were treated with geneticin (16 μM) or gentamicin (800 μM) for 24 h. Cycloheximide (16 μM) was used as a negative control,
and tunicamycin (2.5 μg/ml) as a positive control for eliciting UPR. Luciferase activities were determined and the Fluc/Rluc ratios were calculated. Untreated samples are set as 1
and fold inductions are given (n= 3–6, ±S.E.M.). **Po0.01, ***Po0.005. (h) Phosphorylated eIF2α was detected by immunofluorescence. HEK wild-type cells were treated
with geneticin (16 μM) for 24 h or arsenite (0.5 mM) for 1 h as a positive control. Scale bars: 40 μm. The lower panels show insets in higher magnification. Bar graph indicates
quantification of p-eIF2α immunofluorescence (n number of cells; nUn= 540; nGen= 249; nArs= 648); ****Po0.001. Ars, arsenite; CHX, cycloheximide; Gen, geneticin; Gm,
gentamicin; Hyg, hygromycin; Tm, tunicamycin; Un, untreated
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As a further element of the UPR, we studied splicing of XBP1
mRNA, which is central for UPR activation.11 Both geneticin
and gentamicin induced XBP1 splicing (Figure 3d). In
contrast, XBP1 splicing was induced neither by the non-
misreading aminoglycoside hygromycin42 nor by cyclo-
heximide, an inhibitor of ribosomal translocation,43 indicating
that XBP1 splicing depends on misreading and not on
inhibition of translation. Furthermore, the presence of APH
(3′) in HEK cells abrogated geneticin-induced but not
gentamicin-induced XBP1 splicing.
The activity of transcription factors XBP1 and ATF6 was
examined using reporter plasmids UPRE (p5xATF6-GL3-luc)
and ERSE (pGL3-GRP78P(-132)-luc).44,45 The UPRE repor-
ter is specific for ATF6 activity, the ERSE reporter is regulated
by both ATF6 and XBP1.44,45 Both reporters showed a robust
induction by geneticin and gentamicin (Figures 3f and g).
Cycloheximide failed to induce any reporter activity consistent
with the XBP1-splicing results (Figures 3d, f and g). The
PERK signaling branch was investigated by assessing the
formation of stress granules, cytosolic protein aggregates
composed of 48 S preinitiation complexes and other factors.
Stress granules are induced upon activation of PERK and
phosphorylation of eIF2α.46 Treatment of HEK wild-type
cells with geneticin for 24 h increased immunostaining
against phosphorylated eukaryotic initiation factor 2 alpha
(p-eIF2α) in a dotted cytosolic distribution consistent with
the formation of stress granules (Figure 3h). Arsenite
treatment served as a positive control. A similar robust
induction of UPR by aminoglycosides was observed in HeLa
cells (Supplementary Figure S3).
Gentamicin induces ER stress in SGCs but not in
auditory hair cells. To study the response of auditory hair
cells to ER stress, we first used tunicamycin, an established
ER stress inducer in early post-natal cochlear explants of the
CBA/J mouse, a common strain for auditory research.
Preliminary experiments (data not shown) with hair cell
counts on surface preparations had established incubation
with 0.07 μg/ml tunicamycin as a suitable treatment with hair
cell death beginning at 48 h and encompassing 50% of cells
by 72 h. The ER stress-associated pro-apoptotic factor
CHOP already appeared after 8 h of incubation with
tunicamycin and was expressed in the nuclei of most hair
cells by 24 h (Figure 4a and Supplementary Figure S4).
Staining mostly had disappeared at 48 h (Supplementary
Figure S4) when loss of hair cells became apparent,
implicating CHOP as an indicator of impending hair cell
death. In the same explant model, treatment with gentamicin
produced significant loss of hair cells with the pattern of loss
showing the typical progression of aminoglycoside damage47
causing most destruction in the base (Supplementary Figure S5),
whereas inner hair cells (IHCs) were mostly spared.
Figure 4 ER stress in cochlear tissues. (a) Tunicamycin but not gentamicin causes ER stress in hair cells. Tunicamycin (0.07 μg/ml) induced the specific ER stress-
associated pro-apoptotic factor, CHOP (green), in the nuclei of hair cells in organ of Corti explants by 24 h. In contrast, CHOP was not observed in any part of the organ of Corti
throughout the entire time course of gentamicin treatment (3.5 μM) until hair cell death. Segments shown are from the basal turn. Green: CHOP (GADD 153 antibody), red:
myosin 7a antibody, blue: Hoechst 33342 staining for nuclei. The focal plane is at the nuclear level of outer hair cells leaving some regions stained against myo7a out of focus. The
figure represents three different explants at each time point. Scale bar (Gm): 10 μm. (b) Gentamicin induces ER stress in SGCs. Tunicamycin (0.07 μg/ml) treatment for 24 h
induced CHOP in the nuclei of SGCs (arrows). With gentamicin treatment (3.5 μM), CHOP appeared in the nuclei of SGCs by 48 h (arrows). Green: CHOP (GADD 153 antibody),
red: neuronal class III β-tubulin staining for SGCs, blue: Hoechst 33342 staining for nuclei. The figure represents three different explants at each time point. Scale bar, 10 μm
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Despite continuing and increasing cell death, CHOP was not
observed throughout the entire time course up to 72 h
(Figure 4a).
The response of ganglion neurons to ER stress was studied
in SGCs that were harvested from the base to themiddle of the
modiolus of cochlear explants and similarly treated with
tunicamycin or gentamicin (Figure 4b). As expected from its
activity as an ER stressor, tunicamycin induced CHOP in the
nuclei of SGCswithin 24 h. In contrast to its effect on hair cells,
gentamicin increased the immunoreactivity to CHOP in SGCs,
evident after 48 h of incubation.
Gentamicin reduces the number of SGCs and synaptic
ribbons but not hair cells in XBP1+/− mice in vivo. In wild-
type strains such as the CBA/J mouse, the outer hair cells
(OHCs) are the primary target of chronic aminoglycoside
ototoxicity in vivo48 and very little direct effect – if any – can
be observed on SGCs. In view of the modest but significant
gentamicin-induced CHOP expression in SGCs of cochlear
explants, we investigated potential consequences of
gentamicin-induced ER stress in a model of compromised
UPR, an XBP1-haploinsufficient mouse. The local route of
drug administration to the middle ear, chosen for this study, is
able to isolate effects to the auditory periphery while avoiding
adverse complications associated with systemic gentamicin
treatment in the mouse.30 Preliminary experiments with a
series of gentamicin concentrations starting at 0.09M
established 0.56M as a suitable dose that caused a
moderate auditory threshold shift while avoiding major
pathophysiology (data not shown).
Surface preparations from XBP1+/− and wild-type litter-
mates locally treated with gentamicin in vivo were examined
from base-to-apex 3 weeks after drug injection. OHCs were
present in all parts of the cochlea in both wild-type and
XBP1+/− mice except for some scattered loss at the very end
of the basal turn (Supplementary Figure S5c). Quantitation of
hair cell loss along the entire cochlea confirmed only minor
damage at the extreme, the basal turn with no difference
between wild-type and XBP1+/− mice.
In the absence of any discernible defects on hair cell
integrity and prompted by the in vitro results, we then analyzed
spiral ganglion density and synaptic connections. Three
weeks after gentamicin injection, the SGCs were counted on
mid-modiolar cryosections stained for β-tubulin and nuclei.
There was a significant reduction in spiral ganglion density in
the basal turn of the cochlea in XBP1+/− mice but not in wild-
type littermates (Figures 5a and b). The innervation of hair
cells by the spiral ganglion was assessed by staining synaptic
ribbons with antibody to CtBP2, a constituent of the ribbon
protein RIBEYE. Gentamicin reduced the number of synaptic
ribbons per IHC by approximately 50% in the basal turn of the
cochlea of the XBP1+/− mice but not of corresponding wild-
type littermates (Figures 5c and d).
Auditory physiology corroborates auditory pathology
and ER stress. In order to assess the impact of the
observed pathology on auditory function, we measured
auditory brainstem responses (ABRs) and distortion product
otoacoustic emissions (DPOAEs). ABR provides information
on the ascending auditory pathway reflecting synaptic and
neuronal activity, whereas DPOAE probes the functional
integrity of OHCs. Deterioration of auditory thresholds was
apparent 1 week after the injection of gentamicin and
remained stable for up to 3 weeks, the latest time point
studied (Figure 6a). Large threshold shifts were observed at
32 kHz in XBP1+/− mice but not in wild-type littermates,
which were little affected. Consistent with the morphological
observations of intact OHCs, DPOAE remained unaffected by
gentamicin treatment (Supplementary Figure S6).
Finally, in order to validate the potential contribution of
protein misfolding to the gentamicin-induced changes in
auditory thresholds, we treated animals with tauroursodeoxy-
cholic acid (TUDCA), a clinically used chemical chaperone.
Systemic TUDCA co-administration significantly attenuated
gentamicin-induced ototoxicity in the XBP1+/− mice (Figure 6b)
as measured by ABR 3 weeks after the drug treatment.
Discussion
Aminoglycoside-induced loss of translational fidelity in eukar-
yotes is evident from our experiments on HEK293 cells and,
moreover, is clearly linked to the ribosomal activity of the
drugs. The known misreading inducers geneticin and genta-
micin, but not the non-misreading aminoglycoside hygromycin
or the ribosomal translocation inhibitor cycloheximide, elicit a
UPR. Gentamicin was selected as a classical clinical
aminoglycoside to bridge the findings from our in vitro studies
to the animal model. Geneticin was included because its
inactivation by the APH(3′) enzyme allowed to control for the
specificity of drug action.39 Modification of geneticin by APH
(3′) (which abrogates its anti-ribosomal activity by phosphor-
ylation of the 3′ OH group) indeed eliminated its ability to
cause both misreading and ER stress. In contrast, APH(3′) did
not affect the misreading activity of gentamicin, which lacks
the 3′ OH group and thus is not a target for APH(3′).
We had primarily chosen HEK293 cells for study as these cells
are readily transfected, facilitating the useof reporter constructs to
study drug-induced misreading49 but similar results in human
HeLa cells suggest the general nature of this response. The
finding that the cell viability and themetabolic activity of HEKwild-
type cells remain intact despite drug-induced mistranslation
attests to the protective efficacy of cellular homeostatic responses
such as the UPR and allows us to extrapolate that the UPR, at
least in part,mitigatesmistranslation induced byaminoglycosides
in eukaryotic organisms.
Consistent with this notion, XBP1+/− haploinsufficient mice
but not wild-type mice sustain gentamicin-induced loss of
SGCs. XBP1 is one of the central components in the three
canonical pathways of the UPR, regulating molecular chaper-
ones and promoting ER-associated degradation.50 The crucial
function of XBP1 for cell survival is evident from the embryonic
lethality of homozygous XBP1 knock-out mice.37 Haploinsuffi-
cient mice are viable but are less capable of inducing
chaperones and promoting ERAD under ER stress
conditions.51 Consequently, ER stress is prone to damage
cells in XBP1+/− but not in wild-type mice.
Aminoglycoside-induced death of hair cells hasmostly been
associated with inhibition of host-cell protein synthesis47,52
and oxidative stress,48 and evidence for an involvement of ER
stress in ototoxicity has been indirect or lacking. Upregulation
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of heat shock proteins protects the mouse inner ear in part
from aminoglycoside-induced ototoxicity in vivo.53 However,
the ER stress marker m-calpain is unaffected by aminoglyco-
side treatment in the mouse cochlea in vivo.54 We show here
that no ER stress marker develops in hair cells despite the
extensive damage that gentamicin causes in cochlear
explants. This is in contrast to the action of the ER stressor
tunicamycin, a finding consistent with previous observations
of tunicamycin-induced hearing loss in the rat.55 Further
distinguishing the pathological mechanisms of the two drugs,
the hair cell loss caused by tunicamycin broadly encompasses
all regions of the cochlea, whereas the pattern of gentamicin-
induced damage in the explants follows the base-to-apex
gradient characteristic of aminoglycosides.48
Our results clarify that aminoglycosides can induce ER
stress in mammalian tissues, including the inner ear. In
agreement with our results, markers of ER stress have also
been observed in rat kidneys as part of the nephrotoxic actions
of gentamicin treatment.56 In the cochlea, drug-induced ER
stress is limited to neurons of the spiral ganglion. In the in vivo
model presented here, a single low dose of gentamicin does
not lead to hair cell death. However, SGCs were significantly
reduced in the base of the cochlea, corroborating the in vitro
results on ER stress in the nerve but not in hair cells. In accord
with a decreased density of SGCs, synaptic connections to hair
cells are lost, providing an explanation for the observed high-
frequency threshold shift. It is interesting in this context that a loss
of afferent nerve terminals and subsequent degeneration of the
cochlear nerve has also been observed after moderate noise
exposure that leaves the sensory cells intact.57
On a mechanistic level, disruption of translational fidelity
causes protein misfolding and aggregation. The ability of
XBP1 to maintain cell integrity upon drug-induced mistransla-
tion appears to be mediated by induction of ER chaperones
such as BiP, which we find to be upregulated. Consequently,
the selective actions of gentamicin on SGCs and synapses
suggest a heightened sensitivity to neurodegeneration in the
XBP1+/− haploinsufficient mice. Although our results imply an
important role for XBP1, additional investigations are required
to address its exact role in aminoglycoside-induced ER stress,
Figure 5 Gentamicin reduces the number of SGCs and IHC synapses in the basal turn of XBP1+/− mice cochleae. Gentamicin (0.56 M) was locally injected into the middle ear
through the bulla as described in the Materials and Methods section ‘Drug administration in vivo.’ (a and b) Gentamicin reduces SGCs in XBP1+/− but not in wild-type (XBP1+/+)
littermates. (a) The number of SGCs was counted from high-magnification images of Rosenthal’s canal of saline- or gentamicin-injected wild-type and XBP1+/− mice. Red: neuronal
class III β-tubulin staining for neural cells, blue: Hoechst 33342 staining for nuclei. The figure represents five different animals at each condition. Scale bar: 50 μm. (b) Quantitative
evaluations revealed that SGC density in the basal turn of XBP1+/− mice but not in wild-type mice was significantly decreased by gentamicin. Filled bars, controls; open bars,
gentamicin treatment. n= 5 in each group; **Po0.01. Middle and apical turnswere not affected. (c and d) Gentamicin reduces synaptic ribbons in XBP1+/− but not in wild-type mice.
(c) Hair cells were stained with anti-myo7 antibodies (red) and synaptic ribbons with antibodies to CtBP2 (green). The number of synaptic ribbons per IHC in the basal turn was
quantified from 3-D images created by using Imaris software. Staining of some nuclei is consistent with a partial nuclear localization of CtBP2,66 which has been confirmed for IHCs.67
The figure represents three different animals at each condition. Scale bar: 20 μm. (d) Quantitative evaluations demonstrated that synaptic ribbon density of XBP1+/− mice but not of
wild-type littermates was diminished by local injection of gentamicin. Filled bars, controls; open bars, gentamicin treatment. n= 3 in each group; **Po0.01
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given the frequent intercalation of the three branches of the
UPR.12,50
Protein misfolding has been associated with a variety of
disorders collectively termed conformational diseases.58
Presumably, cell-type-specific differences in the buffering
capacity of the proteostasis network account for the cell or
organ selectivity in some of these diseases.59 The hypothesis
presented here that loss of SGCs in XBP1+/− haploinsufficient
mice is conferred by the drug’s misreading activity is
supported in vivo by the observation that administration of a
chemical chaperone significantly alleviated the gentamicin-
induced hearing loss. Specifically, we postulate that the UPR
is normally able to maintain a protein folding equilibrium in the
presence of aminoglycoside-induced mistranslation in SGCs.
However, when the UPR system is compromised, for example,
by genetic haploinsufficiency of XBP1, aminoglycoside-
induced mistranslation can manifest as neuropathology.
Materials and Methods
Materials and sources. Mouse monoclonal anti-GADD 153 (B-3) antibody
(Santa Cruz Biotechnology, Dallas, TX, USA); polyclonal antibody against neuronal
class III β-tubulin (Covance, Princeton, NJ, USA); monoclonal anti-CtBP2 antibody
(BD Biosciences, San Jose, CA, USA); polyclonal antibody against p-eIF2α (Cell
Signaling, Danvers, MA, USA); polyclonal anti-myosin 7a antibody (Proteus
Biosciences, Ramona, CA, USA); secondary goat anti-rabbit antibody conjugated
with Texas Red (Abcam, Cambridge, MA, USA); rhodamine phalloidin, Invitrogen
(Life Technologies, Carlsbad, CA, USA); HEK293 cells (Innoprot, Biscay, Spain);
geneticin, gentamicin, tunicamycin, cycloheximide, arsenite, saponin and HEK aph
(3′) cells (Sigma Aldrich, St. Louis, MO, USA); hygromycin (PAA Laboratories,
Cansera, Canada); nucleotide primers (Microsynth, Balgach, Switzerland); cell
culture media and trypsin (Life Technologies).
Assessment of mistranslation. Misreading and stop codon readthrough
were assessed in gain-of-function dual-luciferase assays.60,61 For translation in
RRLs (Promega, Madison, WI, USA), luciferase mRNA was produced in vitro using
T7 RNA polymerase (Thermo Scientific, Waltham, MA, USA) and plasmids pGL4.14
(humanized firefly luciferase, hFluc) and pGL4.75 (humanized renilla luciferase,
hRluc; both from Promega), where the mammalian promoter was replaced by the
T7 bacteriophage promoter. For misreading, we replaced residue His245 (CAC
codon) with Arg245 (CGC near-cognate) in the hFluc protein by site-directed
mutagenesis. Readthrough was assessed with a fusion construct in which hRluc
and hFluc were fused by a 27-nucleotide linker encoding the polypeptide
STCDQPFGF, using overlap PCR mutagenesis to result in the pT7 hRluc-hFluc
vector; a UGA nonsense-codon was introduced at the glutamine residue (wild-type
CAA) of the linker sequence by site-directed PCR mutagenesis. A cell-free
luciferase translation assay was performed as described.60
Mistranslation in HEK cells was determined using the pRM hRluc-hFluc H245R
vector, where His245 (CAC codon) was replaced by Arg245 (CGC codon) in the pRM
hRluc-hFluc vector. Readthrough was determined by pRM hRluc-hFluc D357X,
where Asp357 (GAC codon) was replaced by a UGA nonsense-codon in the firefly
luciferase transcript. Both constructs were designed by site-directed PCR
mutagenesis. HEK wild-type cells were transfected with reporter plasmid using
TurboFect (Fermentas, Vilnius, Lithuania) according to the manufacturer‘s protocol.
After a 24-h incubation, medium was replaced by F10 with 15 μg/ml saponin.
Aminoglycoside antibiotics were added and cells were incubated for another 24 h.
Cells were lysed and luciferase activities determined; hRluc mRNA was used as an
internal control and misreading and readthrough were quantified by calculating
mutant firefly/renilla activities. The basal error frequency of the eukaryotic ribosome62
is 4 × 10–4 to 10–5. For each set of replicates, the hFluc/hRluc ratio of the untreated
samples were set as 1, which reflects this basal error frequency. Luminescence was
measured in a luminometer FLx800 (Bio-Tek Instruments, Winooski, VT, USA).
Viability assay. HEK cells were grown to 70% confluence and treated for the
indicated time with 16 μM geneticin or 400 μM gentamicin in F10 medium with
15 μg/ml saponin. Ten percent Alamar Blue solution was added (v/v) for 3 h and
fluorescence was monitored at 530 nm for excitation and 590 nm for emission.
Figure 6 Auditory threshold shifts are induced by gentamicin and protected by
TUDCA. (a) Gentamicin (0.56 M) was locally injected into the middle ear through the
bulla as described in ‘Materials and Methods’ section. Three weeks after treatment,
large threshold shifts had developed at 32 kHz in XBP1+/− mice (square symbols)
but not in wild-type littermates (circles). Data are presented as mean+S.D. for
XBP1+/− mice and mean–S.D. for wild-types. n= 6 in each group; **Po0.01.
(b) TUDCA attenuates gentamicin ototoxicity in XBP1+/− mice. Animals in all three
groups received the local injection of gentamicin and, as indicated, TUDCA
co-treatment (500 mg/kg sc.) at 6 days, 3 days and 3 h before gentamicin injection.
Data are presented as means + S.D. of threshold shifts at 32 kHz, determined
3 weeks after treatment. n= 6 in each group; **Po0.01
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The fluorescence level of the control sample (untreated) was set as 100% after
subtraction of background fluorescence, measured in cell-free wells.
Sytox dead cell stain. HEK cells were grown to 60% confluence in DMEM
with 10% fetal bovine serum (FBS). Medium was changed to F10 with 15 μg/ml
saponin and aminoglycoside antibiotics were added and cells were incubated for 24
or 48 h. Cells were detached by adding 100 μl accutase (Life Technologies) and
were resuspended in 400 μl FACS buffer (1x phosphate-buffered saline (PBS), 2%
FBS) and transferred to FACS tubes. Sytox Red (Life Technologies) was added to
the cell suspension. The nucleic acid stain penetrates cells with compromised
plasma membranes but will not cross uncompromised cell membranes. The
samples were then analyzed with a BD FACS Canto II (BD Biosciences, Allschwil,
Switzerland) and the FlowJo data analysis software (FlowJo, Ashland, OR, USA).
Microarray analysis. See the legend of Supplementary Figure S2.
Proteome analysis. Cell samples were incubated with lysis buffer (150 mM
NaCl, 0.1% SDS, 0.5% Na-deoxycholate, 50 mM Tris pH 7.5 and 1 × complete
protease inhibitor (Roche, Rotkreuz, Switzerland)) for 10 min at room temperature
(RT) on a shaking mixer. The lysate was ultrasonicated for 10 min and centrifuged
for 20 min at 16 000 × g at 4 °C. Eighty micrograms of protein of each sample were
used for iTRAQ labeling (AB SCIEX, Framingham, MA, USA).
Each iTRAQ 4-plex experiment was carried out with two biological replicates of
untreated HEK wild-type cells (114 and 116 label) and two biological replicates of
cells treated with 16 μM geneticin for 32 h (115 and 117 label) following the
manufacturer's protocol. iTRAQ samples were pooled, dried, reconstituted in solvent
A (5% ACN, 8 mM KH2PO4 and pH 4.5), and fractionated by HILIC-HPLC (Pack
Polyamine II, 250 × 4 mm, 120 Å S-5 μm, YMC). The column was equilibrated with
solvent A. Peptides were eluted using solvent B (5% ACN, 100 mM KH2PO4 and pH
4.5) by a gradient of: 0–7.5 min, 0% B; 7.5–37.5 min, 0–50% B; 37.5–42.5 min,
50–100% B; 42.5–47.5 min, 100% B at a flow rate of 0.4 ml/min. The resulting 13
fractions were desalted using ZipTips (Millipore, Billerica, MA, USA) according to the
manufacturer’s protocol and reconstituted in solvent C (3% ACN and 0.1% formic
acid) for LC-MS/MS analysis. Samples were auto-injected into an Eksigent-nano-
HPLC system and separated on a custom reverse phase tip column (75 μm 150 mm)
packed with C18 material (3 μm, 200 Å, AQ, Bischoff GmbH, Leonberg, Germany).
The column was equilibrated with solvent C and 5% solvent D (0.2% FA in ACN). For
elution, a flow rate of 300 nl/min was used and a gradient of 0–70 min, 5–25% D;
70–85 min, 25–50% D; 85–88 min, 50–98% D. High accuracy mass spectra were
acquired with an AB SCIEX 5600 mass spectrometer (AB SCIEX) in the range of
385–1250 m/z. Up to 36 data-dependent MS/MS were recorded in high sensitivity
mode of the most intense ions with charge states 2+, 3+ and 4+ using collision-
induced dissociation. Target ions already selected for MS/MS were dynamically
excluded for 90 s after three occurrences. MS/MS data were analyzed using Mascot
2.4 (Matrix Science, Boston, MA, USA) and searched against a decoyed human
database from Swissprot (Lausanne, Switzerland; release December 2012)
concatenated with an in-house build contaminant database. The search parameters
were: precursor ion mass tolerance of 20 p.p.m., fragment ion mass tolerance of
0.05 Da, trypsin digestion, fixed modifications of MMTS-labeled cysteine, 4-plex
iTRAQ modifications of free amines at the N-termini and of lysine and variable
modification 4-plex iTRAQ of tyrosine. Peptides without 4-plex iTRAQ labeling at the
N-terminus or at a lysine were excluded from the analysis. Scaffold_4.1 (Proteome
Software Inc., Portland, OR, USA) was used to validate MS/MS-based peptide and
protein identifications. We identified and quantified 1785 proteins (protein prophet
probability 95%, minimum two peptides for identification of a protein and minimumMascot
Ionscore of 40). After the permutation test and further amendment of the P-value with the
Bonferroni correction, 77 proteins were found to be regulated (P-valueo0.05). Thirty-five
proteins were upregulated based on a threshold of 0.3 (log2 scale).
XBP1-splicing assay and qPCR. RNA samples from HEK cells were
prepared using Trizol extraction (Life Technologies) and were reverse transcribed
using a ThermoScript RT-PCR System (Life Technologies) according to the
manufacturer's instructions. The XBP1-splicing assay used XBP1-specific primers
that amplify spliced (−26 nt) and unspliced XBP1 mRNA (forward 5′-TTACG
AGAGAAAACTCATGGCC-3′, reverse 5′-GGGTCCAAGTTGTCCAGAATGC-3′).
PCR products were analyzed on a 2.7% agarose gel. Amplification of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA served as loading
control. For qPCR the Quantitect SYBR Green PCR Kit (Qiagen, Hilden, Germany)
was used together with the 7500 Fast Real-Time PCR System (Applied Biosystems,
Zug, Switzerland). The primers were CHOP: forward 5′-GCGCATGAAGGAGA
AAGAAC-3′, reverse 5′-CCAATTGTTCATGCTTGGTG-3′; BiP: forward 5′-TTTCT
GCCATGGTTCTCACTAAAA-3′, reverse 5′-AACATTTAGGCCAGCAATAGTTCC-3′;
GAPDH: forward 5′-ACCCACTCCTCCACCTTTGA-3′, reverse 5′-CTGTTGCTG
TAGCCAAATTCGT-3′; GRP94 forward 5′-TGGGAAGAGGTTCCAGAATG-3′, reverse
5′-GTTGCCAGACCATCCGTACT-3′. For relative quantification, GAPDH mRNA served
as a reference. Measured quantification cycles were analyzed according to Pfaffl,63
comparing treated with untreated samples. Three biological replicates were run in
triplicates each and means and standard deviations were calculated.
Western blot. HEK cells were grown to 60% confluence in DMEM with 10%
FBS. Medium was changed to F10 with 15 μg/ml saponin and aminoglycoside
antibiotics were added and cells were incubated for 24 h. Cells were lysed in
hypotonic buffer (20 mM HEPES pH 7.5, 10 mM KCl, 3 mMMg acetate, 1 mM DTT
and 10 μg/ml DNase I) and ultrasonicated. Lysates were centrifuged (13 000 r.p.m.,
10 min) and protein concentration in the supernatant was measured by the Micro
BCA Protein Assay Kit (Thermo Scientific). Ten micrograms of total protein were
resolved on 10% SDS-polyacrylamide gels and blotted on nitrocellulose
membranes, which were probed with specific antibodies. Amersham ECL Prime
Western Blotting Detection Reagent (RPN2232; GE Healthcare, Glattbrugg,
Switzerland) was used as a substrate for the horseradish peroxidase (HRP). The
specific antibodies used in this study were: anti-BiP antibody (Abcam, ab21685);
anti-GRP94 antibody (Abcam, ab87886); anti-ATF4 antibody (Abcam, ab23760); anti-
β-actin antibody (A1978-200UL; Sigma-Aldrich); HRP-conjugated goat anti-rabbit
(Invitrogen, G-21234) and goat anti-mouse antibodies (Invitrogen, A10551).
UPR reporter assay. Reporter plasmids UPRE (p5xATF6-GL3)44 and ERSE
(pGL3-GRP78P(-132)-luc)45 carrying luciferase under the control of UPR-specific cis-
acting elements were kind gifts from Kazutoshi Mori (Kyoto University, Japan). HEK
cells were grown to 60% confluence and co-transfected with reporter constructs and
pGL4.75 (Rluc) using TurboFect reagent (Fermentas) according to the manufacturer’s
protocol. After a 24-h incubation, medium was replaced by F10 with 15 μg/ml saponin.
Aminoglycosides were added and cells were incubated for another 24 h. Cells were
lysed and luciferase activities determined. Normalization of luciferase activities was
performed as described above. Cycloheximide was used as a mistranslation negative
control and tunicamycin was used as a positive control for UPR.
P-eIF2α immunofluorescence assay. HEK cells grown on poly-D-lysine
(Sigma Aldrich)-coated cover slips (Thermo Scientific) were treated for 24 h with
geneticin in F10 medium with 15 μg/ml saponin, or with arsenite for 1 h (positive
control). Cells were then fixed with 4% paraformaldehyde and methanol and
incubated with blocking solution (1 × PBS with 1% BSA and 0.5% saponin) for 1 h
at RT. Immunostaining used a rabbit polyclonal antibody against p-eIF2α (1 : 250)
and a secondary goat anti-rabbit antibody conjugated with Texas Red (1 : 250)
diluted in blocking solution. Cover slips were mounted on glass slides (VWR) using
Dapi fluoromount (Southern Biotech, Birmingham, AL, USA), and cells were imaged
using a Lyca Sp2 confocal microscope and a 63 × objective. p-eIF2α and nuclear
signals were quantified using Imaris software (Bitplane, Belfast, UK) and the dots-
per-cell ratio was calculated.
Animals. Male and female CBA/J mice were purchased from Harlan Sprague-
Dawley Co. (http://www.harlan.com/products_and_services/research_models_and_
services/research_models/cbaj_inbred_mice.hl) at an age of 6–8 weeks and bred
in-house in order to obtain pups for organotypic cultures of the post-natal organ of
Corti and SGCs (see next section). XBP1+/− mice were from a stock kindly
provided by Dr. Laurie H Glimcher and received via Dr. Randal J Kaufman,
University of Michigan. Littermates served as wild-type (XBP1+/+) controls. Animals
were kept on a 12-h light/12-h dark cycle with free access to water and diet (Purina
5001, Lab Diet, St. Louis, MO, USA) and used in the in vivo studies at an age of
3–4 months. Experimental protocols were approved by the University of Michigan
Committee on the Use and Care of Animals and animal care was under the
supervision of the University of Michigan’s Unit for Laboratory Animal Medicine.
Organotypic cultures of post-natal organ of Corti and SGCs. The
procedures were as described previously.64 Mice at post-natal day 2–3 (p2–3) were
killed and cochleae dissected in cold Hank’s Balanced Salt Solution to isolate the
organ of Corti; SGCs were dissected from the base to the middle of the modiolus.
Explants were placed onto a culture dish in 2 ml of medium consisting of basal medium
Eagle, 1% serum-free supplement (Gibco #51500-056, Life Technologies, Grand Island,
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NY, USA), 1% bovine serum albumin, 5 mg/ml glucose and 10 U/ml penicillin G, allowed
to settle for 4 h (37 °C, 5% CO2) and incubated for 2 days to mitigate dissection stress.
Medium was then exchanged for new media with or without drugs and incubation
continued. For immunofluorescent labeling, explants were fixed with 4% paraformalde-
hyde overnight at 4 °C and permeabilized for 30min with 3% Triton X-100 in PBS at RT.
After three washes with PBS and blocking with 10% goat serum for 30 min at RT,
incubation with the primary antibodies followed at 4 °C for 72 h. After three washes with
PBS, secondary antibodies were applied (Alexa Fluor 488-conjugated goat anti-mouse
and Alexa Fluor 546-conjugated goat anti-rabbit antibody; 1 : 200 in PBS) at 4 °C
overnight in darkness. After several rinses, specimens were mounted on a slide with
Prolong Gold anti-fade reagent (Life Technologies) and imaged with an Olympus
Fluoview Confocal Laser Scanning Microscope-FV500 (Olympus America, Center
Valley, PA, USA). For staining of hair cells, specimens were incubated at RT with
rhodamine phalloidin (1 : 100) for 1 h; or for staining of nuclei with Hoechst 33342 (2 μg/
ml in PBS) for 40 min. Presence or absence of OHCs and IHCs was determined on a
Leitz Orthoplan microscope (Leica, Wetzlar, Germany) whose right objective had a
0.19-mm scale imposed on the field. Successive 0.19-mm fields were evaluated
beginning at the apex by observers blinded to the experimental conditions. Cell counts
were compared with a normative database (KHRI Cytocochleogram, version 3.0.6,
Kresge Hearing Research Institute, University of Michigan, Ann Arbor, MI, USA).
Drug administration in vivo. Gentamicin was locally delivered as previously
described.65 Mice were anesthetized with an intraperitoneal injection of xylazine
(7 mg/kg) and ketamine (90 mg/kg) and body temperature was maintained. The
temporal bone was approached via a retro-auricular incision and a small hole was
made in the thin part of the bulla with a 30-G needle. Surgical tubing was inserted
through the hole, and 10 μl of 0.56 M gentamicin dissolved in saline was slowly
injected. The skin incision was closed with tissue adhesive. TUDCA (Calbiochem,
EMD Millipore) was dissolved in 0.15 M NaHCO3 (adjusted to pH 7.4) and injected
subcutaneously at 500 mg/kg body weight 6 days, 3 days and 3 h before gentamicin
administration. Injections of 0.15 M NaHCO3 served as vehicle controls. Injection of
TUDCA did not cause any apparent side effects.
Hair cell counts in adult mice. Three weeks after injections, cochleae were
fixed as described above. The apical bony capsule was removed and the cochlea
decalcified in 4% sodium EDTA (adjusted to pH 7.4) for 7 days at 4 °C.
Subsequently, cochleae were dissected into apical, middle and basal segments.
Segments were permeabilized in 3% Triton X-100 for 30 min at RT, washed three
times with PBS and incubated with rhodamine phalloidin (1 : 100) at RT for 1 h. The
procedures for cell counting were the same as for explants.
Quantification of SGCs and synaptic ribbons. Following decalcifica-
tion with 4% EDTA, cochleae were cryo-sectioned. Sections of 8 μm thickness were
incubated in 0.3% Triton X-100 in PBS for 30 min at RT, blocked with 10% goat
serum for 30 min, followed by incubation with anti-neuronal class III β-tubulin
antibody (1 : 2000) for 48 h at 4 °C. After three rinses in PBS, sections were
incubated with a secondary antibody (Alexa Fluor 546-conjugated; 1 : 500) at 4 °C
overnight in darkness. After three washes with PBS, sections were stained with
Hoechst 33342 (2 μg/ml in PBS) for 40 min at RT. After a final wash, the slides were
mounted with Prolong Gold anti-fade reagent. Controls were processed without
primary antibody. The number of SGCs in Rosenthal’s canal was quantified using
ImageJ software (National Institutes of Health, Bethesda, MD, USA) by counting the
β-tubulin- and Hoechst-positive cells on images taken with an Olympus laser
confocal microscope. Two mid-modiolar sections, separated by 40–50 μm, were
used to obtain the average for each animal. For synaptic ribbon counts,
cryosections were incubated for 30 min at RT with 5% donkey serum in PBS with
0.3% Triton X-100 and overnight in darkness at 4 °C with antibodies against CtBP2
(1 : 200) and Myo7a (1 : 200). After three washes in PBS (15 min each), tissues were
incubated with secondary antibodies (Alexa Fluor 488- and Alexa Fluor 546-conjugated;
1 : 1000) at RT for 1 h. After three washes, the epithelia were mounted and images
taken on an Olympus laser confocal microscope. Images were reconstructed three-
dimensionally using Imaris software (Bitplane). The number of synaptic ribbons was
quantified per IHC based on an average of 14 IHCs per sample.
Auditory function measurements. For ABRs, animals were anesthetized
with an intraperitoneal injection of xylazine (7 mg/kg), ketamine (65 mg/kg) and
acepromazine (2 mg/kg), and placed in a sound-isolated and electrically shielded
booth (Acoustic Systems, Austin, TX, USA). Body temperature was maintained near
37 °C with a heating pad. Acoustic stimuli were delivered monaurally to a Beyer
earphone attached to a speculum inserted into the left ear canal. Subdermal
electrodes were inserted at the vertex of the skull, under the left ear and under the
right ear (ground). ABRs were measured at 12 and 32 kHz using Tucker Davis
Technology (TDT) System III hardware and SigGen/Biosig software (Tucker Davis
Technology, Alachua, FL, USA) to present the stimuli (15 ms tone bursts, 1 ms rise-
fall time) and record up to 1024 responses for each stimulus level. Thresholds were
determined by reducing the intensity in 10-dB increments and then in 5-dB steps
until no organized responses were detected. Threshold shifts were calculated for
individual animals as the difference in auditory thresholds between ABR
measurements before and at the end of the studies. For the DPOAE procedure,
see the legend of Supplementary Figure S6.
Statistical analysis. Data were evaluated by one-way ANOVA followed by
Tukey’s honestly significant difference tests using JMP version 8.0.1 (SAS Institute
Inc., Cary, NC, USA) or Student’s t-test. All tests were two-sided with significance
set at Po0.05.
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